Key Takeaway:
- Weight-Loss Drugs to Lower Cancer Risk were associated with a 30% reduction in the likelihood of developing breast cancer in a study involving 110,000 women.
- Breast cancer patients using GLP-1 drugs alongside standard treatment showed a 30% lower risk of death.
- Researchers say the findings are promising, but more clinical studies are needed to confirm whether the drugs directly reduce cancer risk and progression.
Weight-Loss Drugs to Lower Cancer Risk may reduce the chance of developing breast cancer by 30% and also lower cancer-related deaths, according to three studies presented at a major oncology conference in Chicago.
Studies Show Lower Breast Cancer Risk Among GLP-1 Users
Researchers presented findings at the American Society of Clinical Oncology annual meeting suggesting that GLP-1 medications, widely used to treat obesity and Type 2 diabetes, could become part of future cancer prevention and treatment strategies.
One study analyzed health records from 110,000 women ages 45 to 80 and found that those taking GLP-1 drugs were 30% less likely to develop breast cancer than women who did not use the medications.
Dr. Elizabeth McDonald, a professor of radiology at the University of Pennsylvania and a breast radiologist at the Abramson Cancer Center, said the findings add to growing evidence that the drugs may have benefits beyond weight loss.
“While our study was observational and does not definitively confirm an association between GLP-1 medications and reduced breast cancer incidence, it does add to the growing body of evidence suggesting that it’s worth investigating these weight-loss drugs as potential cancer prevention tools,” McDonald said.
Breast cancer remains the most common cancer among women worldwide. Obesity, particularly after menopause, is a known risk factor for the disease.
Researchers Report Improved Survival Rates in Patients
A second study involving 27,000 breast cancer patients found that adding GLP-1 medications to standard cancer treatment was associated with a 30% lower risk of death.
The research was led by scientists at IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, a cancer center in Meldola, Italy.
Researchers explained that Weight-Loss Drugs to Lower Cancer Risk may influence cancer outcomes through several mechanisms, including reducing inflammation and altering biological pathways associated with tumor growth.
McDonald said GLP-1 medications are of interest because they affect multiple processes associated with cancer development despite not being designed as cancer therapies.
“Ultimately, we want to find better options to prevent breast cancer,” she said.
Experts Urge More Research Before Clinical Use
A third study led by the Cleveland Clinic examined 12,000 patients with breast, lung, bowel, and liver cancers. Researchers found patients taking GLP-1 medications were 38% to 50% less likely to develop stage-four disease than those not using the drugs.
Cancer specialists not involved in the studies welcomed the findings but cautioned that more research is needed.
Dr. Marcin Chwistek, director of the supportive oncology and palliative care program at Fox Chase Cancer Center in Philadelphia, said the drugs’ anti-inflammatory and immune-related effects have long suggested broader medical applications.
“GLP-1 receptor agonists have never been just glucose-lowering drugs,” Chwistek said.
Dr. Eleonora Teplinsky, head of breast and gynecologic medical oncology at Valley Health System in New Jersey, said researchers still do not know whether the benefits stem primarily from weight loss or from other biological effects of the drugs.
“I think there is enough data to show there is clearly some impact on either cancer risk or the risk of recurrence, but we haven’t yet defined it exactly,” Teplinsky said.
She called for prospective studies to better understand the relationship and said interest in the field is growing rapidly among cancer researchers.
The studies have not yet confirmed a direct cause-and-effect link between Weight-Loss Drugs to Lower Cancer Risk and reduced cancer incidence, but researchers noted that the findings strongly support further clinical investigation.
Visit Healthcare 360 Magazine For The Most Recent Information.
